International Clinical Trial: Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07213973) titled 'Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa' on Oct. 7.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Incyte Corporation

Condition: Hidradenitis Suppurativa (HS)

Intervention: Drug: Povorcitinib

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: December 14, 2025

Target Sample Size: 40

To know more, visit https://clinicaltrials.gov/study/NCT07213973

Disclai...